Treatment-Timing Effects: When “Earlier Is Better” Needs a Fair Clock
Anas H. Alzahrani, MD PhD MPH
Department of Preventive Medicine and Public Health
Faculty of Medicine, King Abdulaziz University
Treatment-timing effects in observational studies can look beautifully dose-responsive: treatment within six hours appears helpful, within two hours more helpful, and within one hour better still. The curve invites a biological reading. But every narrower window also asks a harder design question: were comparable patients realistically eligible for both strategies at the same clinical moment?
A target-trial label helps only when the emulation specifies a fair clock, feasible strategies, evolving treatment decisions, and enough support for each contrast. Otherwise “earlier is better” may partly mean “the patients treated earlier were different sooner.”
A Current Case: Insulin After Moderate Hyperglycemia in the ICU
A 2026 multicenter target-trial emulation studied 5,755 acutely admitted adults across four ICUs after a first episode of moderate hyperglycemia. It compared insulin initiated within six hours with delayed or no insulin and used targeted minimum loss-based estimation for 30-day mortality.
The abstract reports adjusted mortality of 22.1% with insulin within six hours and 24.4% with later or no treatment, an absolute difference of 2.3 percentage points. Estimates were larger for initiation within one hour and two hours. The authors conclude that the findings support further investigation of initiation timing—not that an ICU treatment rule has been settled.
The clean metaphor
A faster train may truly get you there sooner. But if each departure gate admits different passengers, the timetable alone cannot tell you what speed accomplished.
Interactive timing-claim stress test
Does “Earlier Is Better” Survive a Fair-Clock Audit?
Set only the features you can verify in the protocol and results. This narrows the defensible claim; it is not a risk-of-bias score.
The clock may be selecting the patients
Defensible interpretation
The observed timing pattern is hypothesis-generating. The current information cannot distinguish a biological benefit of earlier treatment from who remained eligible, treatable, and comparable at each time.
What to verify next
- • Rebuild cohort entry at the first qualifying episode and show how treatment assignment during the window was handled.
- • Separate delayed initiation from never initiating, or explain why the combined comparator represents one clinical strategy.
- • Audit post-baseline severity, nutrition, glucose trajectory, contraindications, and competing care that can drive both timing and prognosis.
- • Show that comparable patients had a realistic chance of each strategy, especially in the narrowest early-start window.
Start With the Strategy, Not the Exposure Label
“Insulin within six hours” sounds precise, but a target trial needs more than a received-treatment category. At the first qualifying glucose episode, what actions were available? Did early treatment mean immediate initiation, initiation at any point before six hours, or a dynamic rule triggered by repeated measurements? What treatment, monitoring, glucose target, and rescue care followed initiation?
The comparator matters just as much. “Delayed or no insulin” combines patients who later crossed a treatment threshold, patients whose glucose resolved, patients with contraindications, patients who died early, and patients managed by a different clinical philosophy. That bundle may be necessary for a particular estimand, but it is not automatically one coherent clinical strategy.
| Protocol element | Question a timing claim must answer | Common failure |
|---|---|---|
| Eligibility | Who was eligible for both strategies at the first qualifying episode? | Eligibility depends on later stability or treatment receipt. |
| Assignment | How was treatment during the initiation window allocated analytically? | Future recipients are labeled treated from baseline. |
| Strategy | What action, deadline, target, and post-deadline care define each arm? | Received exposure substitutes for a protocol. |
| Estimand | Is this assignment, adherence, initiation, or a dynamic-regime effect? | The paper moves between these interpretations. |
Time-Varying Confounding Is the Main Event
ICU treatment decisions evolve quickly. Glucose trajectory, organ support, shock, nutrition, corticosteroids, clinician concern, competing procedures, and contraindications may all change after the first qualifying value. These variables can predict both insulin initiation and mortality. Some may also be affected by earlier care.
Baseline adjustment cannot automatically represent that decision process. Ordinary time-updated regression can also fail when a covariate is both affected by prior treatment and a cause of subsequent treatment. Design-aware g-methods can address measured treatment-confounder feedback, but they do not recover variables that were never captured, captured after the decision, or measured too coarsely for an hourly contrast.
Reviewer red flag
The paper presents an hourly timing curve but describes confounding only with admission-level severity scores. The causal clock is finer than the adjustment clock.
The Earliest Window Needs the Strongest Positivity Check
As the initiation window shrinks, the comparison changes. Insulin within one hour may be feasible only in settings with rapid repeat testing, standing protocols, immediate intravenous access, particular staffing, or more obvious clinical concern. Patients and sites without a realistic chance of one-hour treatment cannot identify that contrast without extrapolation.
Report treatment probabilities by time, site, calendar period, and clinically important patient strata. Show the distribution and truncation of any weights, the effective sample size, and sensitivity to alternative models and windows. A smooth estimate does not prove common support; flexible algorithms can interpolate confidently where clinical overlap is thin.
A Timing Gradient Is Not Automatically a Biological Gradient
One-hour, two-hour, and six-hour estimates are usually nested analyses, not independent replications. They reuse much of the same cohort, outcome process, modeling strategy, and unmeasured clinical context. Their differences may reflect biology, but they may also reflect changing composition, treatment support, measurement frequency, and the operational meaning of “early.”
Before narrating the curve, ask whether effect estimates are directly comparable, whether uncertainty around their differences was assessed, and whether the analysis plan prespecified the windows. A monotone visual pattern is useful evidence when the design supports it. It is not a free dose–response argument.
What a Persuasive Timing Study Should Show
- A protocol table. Eligibility, time zero, strategies, assignment, follow-up, outcome, causal contrast, and analysis should align.
- A patient-state timeline. Show what was measured before each treatment decision and at what temporal resolution.
- A comparator decomposition. Describe delayed initiators and never initiators separately before deciding whether to combine them.
- Time-specific support. Report treatment probabilities, weight diagnostics, effective sample size, and site-level feasibility for each window.
- Alternative clocks. Repeat the analysis under defensible definitions of the qualifying episode, treatment deadline, and follow-up start.
- A narrow conclusion. State the strategy contrast actually estimated and keep a treatment recommendation for evidence designed to support one.
Why This Matters for Aqrab
A methodology critique should treat “target trial emulation” as a request to inspect the protocol, not as a quality badge. For treatment-timing studies, that means tracing each result back to a shared time zero, a clinically feasible strategy, the evolving decision state, treatment support, and the population still represented as the window narrows.
Use Aqrab Try to pressure-test whether a timing conclusion outruns its emulated protocol. Teams building repeatable appraisal workflows can use the developer tools to make fair-clock checks explicit across real-world evidence.
Methods Anchors
The applied example is Gantzel and colleagues' ICU insulin target-trial emulation. The article's design questions follow the target-trial framework described by Hernán and Robins and the sustained treatment-strategy guidance by Danaei and colleagues. These sources explain why eligibility, strategy assignment, time zero, adherence, censoring, and time-varying confounding belong to one protocol rather than separate statistical decorations.
Keep reading
Don't stop at one method.
Good methods judgment comes from contrast. Read the neighboring guides, see where the assumptions diverge, and avoid treating every observational problem like it needs the same hammer.
Target Trial Emulation Cannot Randomize Clinical Judgment: A Pertussis Study Audit
A practical target-trial emulation audit using an infant pertussis study. Check clinical-judgment confounding, propensity-score overlap, endpoint timing, sparse outcomes, and claim strength.
Vaccine Effectiveness Without Matching: Why Calendar Time Comes Before Pairing
A practical guide to calendar time in vaccine-effectiveness studies. Learn how changing uptake and infection hazards alter risk sets, estimands, and target-trial conclusions.
Comparator Selection in Observational Studies: Why the Control Group Changes the Question
A practical guide to comparator selection in observational studies. Learn how active comparators change the estimand, confounding structure, and interpretation of real-world evidence.